Gut Microbes and Bile Acids May Protect Against Sleep Apnea-Related Heart Disease
Researchers studying mice found that gut microbes and bile acid signaling play a key role in cardiovascular complications from obstructive sleep apnea. The study identified the farnesoid X receptor (FXR) as central to plaque buildup in arteries during sleep apnea-like conditions, with mice lacking this receptor developing significantly less arterial plaque. These findings could lead to new preventive treatments targeting the gut microbiome or specific bile acids.
A new study presented at ASM Microbe 2026 reveals that gut microbes and their metabolic products may protect against heart disease complications in obstructive sleep apnea, a condition affecting millions worldwide. Researchers compared two groups of mice prone to heart disease—one with normal bile acid signaling and one lacking the farnesoid X receptor (FXR)—and exposed them to conditions mimicking sleep apnea. The results showed that mice without FXR developed significantly less arterial plaque in the aorta and aortic arch, while also experiencing fewer disruptions to their gut microbiome. The findings suggest that microbially modified bile acids signaling through FXR drive the cardiovascular damage seen in sleep apnea. The research team plans to validate these patterns in human datasets and explore whether supplementing specific bile acids or administering key microbes could prevent or reduce disease progression.
What's missing
The study was conducted exclusively in mice; the authors acknowledge plans to examine human datasets but have not yet confirmed whether these mechanisms operate similarly in people with sleep apnea. The specific bile acids and microbes identified as 'key' are mentioned but not named in the available text. Long-term safety and efficacy of potential bile acid or probiotic interventions in humans remain unknown.
What different sources said
- Science DailyCenter
Sleep apnea’s hidden heart disease trigger found in the gut
Related
Person dies from rare Murray Valley Encephalitis virus in Western Australia
A person has died after contracting Murray Valley Encephalitis, a rare mosquito-borne virus, while travelling in Western Australia's north, marking the first reported death from the virus in WA this year. The individual was likely exposed in early May in the West Kimberley region, about 2,000 kilometres north of Perth, before being transferred to a Perth hospital where they died. Health authorities are urging residents and tourists to protect themselves from mosquito bites as the region enters its peak tourism season, noting the virus can cause serious brain infection though complications remain rare.
Shigellosis outbreak in Wayanad rises to three confirmed cases; health officials launch investigation
A third student tested positive for shigellosis in Wayanad, Kerala, following an outbreak at Mar Baselios AUP School, bringing confirmed cases to three. The bacterial infection has caused symptoms in 473 people total, with 58 currently hospitalized, prompting health officials to investigate the source and implement stricter sanitation measures. The outbreak highlights concerns about water safety and food hygiene in the region, with authorities conducting well chlorination and inspections of food establishments.
Red-Light Therapy for Hair Loss: Clinical Evidence and Consumer Device Reviews
Wired published a 2026 guide reviewing red-light therapy devices for hair restoration, reporting that clinical studies suggest the treatment can increase blood circulation, reduce inflammation, and support hair follicle growth. Red-light therapy has emerged as an at-home alternative to traditional hair-loss treatments like topical remedies or surgical procedures. The guide matters because hair loss affects millions, and if clinically validated, at-home devices could democratize access to a non-invasive treatment option.